Analysis of Ciclopirox Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Based on the analysis by Fact.MR, the Global ciclopirox market is estimated to be valued at US$ 11.8 Million in 2023 and it is expected to grow at a CAGR of 5.2% to reach US$ 19.5 Million by the end of 2033.
The rising awareness among people about their hygiene, the increasing number of fungal infections in our surroundings, and the rising demand for anti-fungal treatments are the major drivers of the ciclopirox market. Along with all these factors the change in lifestyle of people, the growing population, and the sudden awareness about healthcare in people also contributes to the overall market expansion of the ciclopirox market.
| Report Attributes | Details |
|---|---|
| Ciclopirox Market Size (2022A) | US$ 11.2 Million |
| Estimated Market Value (2023E) | US$ 11.8 Million |
| Forecasted Market Value (2033F) | US$ 19.5 Million |
| Global Market Growth Rate (2023 to 2033) | 5.2% CAGR |
| US Market Growth Rate (2023 to 2033) | 5.1% CAGR |
| Key Companies Profiled | Kumar Organic Products Limited; Pharmaffiliates; Seqens Group; Fengchen Group Co., Ltd; MuseChem Chemicals; B JOSHI AGROCHEM PHARMA |
Ciclopirox is significantly used as a medication for the treatment of fungal infection in the pharmaceutical industry and is also known as an antifungal agent. Ciclopirox helps in the cure of a variety of fungal infections like (ringworm, nail fungus, and athlete’s foot). It is available in two different forms one is the cream-based form and the other is the powdered form.
In recent years, the ciclopirox market has seen significant market expansion and it is expected that this trend will further continue in the future also.
On the back of the aforementioned findings, the ciclopirox market is anticipated to grow at a CAGR of 5.2% during the forecast period from 2023 to 2033, According to the Fact.MR, a market research and competitive intelligence provider.
“Rapid Increase of the Population Will Lead to an Increase in the Demand of Ciclopirox”
The overall population around us is continuously increasing and it is expected that the total global population will reach 8.5 billion by 2030. With the increase in population, there will be an increased demand for healthcare products also. Ciclopirox is a very common medication for fungal-related infections, and the expanding population is expected to drive the overall growth of the market.
With an increase in the overall population, the basic awareness among people about personal hygiene is also expected to rise substantially, and the demand for anti-fungal products is expected to grow as people will start to be more aware of the importance of personal hygiene leading to an increase in the demand of the ciclopirox.
“Changing Lifestyle of People Will See a Rising Demand for the Ciclopirox Market”
More and more people nowadays are going outside for various work as compared to the number of people in the pandemic days. People now are more exposed to different types of fungal infections due to the change in their lifestyles.
There is a rising sense of awareness among people about the different global issues that this world is facing, because of which more people are nowadays using different forms of public transportation to prevent carbon emissions. This in turn increases the chances of the spreading of different transmissible diseases, fungal infections being one of them. All these changes in the lifestyle of people will drive the market for ciclopirox, as it is one of the best available medications for the treatment of different types of fungal infections.
“High Cost Pose a Barrier to Market Expansion”
Ciclopirox products are relatively very much expensive if compared to their other alternatives, this creates a major barrier to the market expansion of ciclopirox. Fungal infections are such kind of a disease that mostly occurs in people who lack basic hygiene knowledge and are mostly exposed to unhealthy practices, so for them, affordability is one of the biggest factors when choosing the right medication.
For Ciclopirox products, it is a very tough process to get regulatory approval, and because of this, the process becomes very lengthy and expensive. This creates a challenge for the manufacturing companies to create new ciclopirox products at a cheaper price and hence, the ciclopirox products are expensive in general, causing a market barrier for further expansion.
“Rising Competition From Alternative Antifungal Agents”
There are several different antifungal agents available in the market for the treatment of fungal infections, and because of the many choices, it will pose a major barrier to the market expansion of ciclopirox.
China is one of the fast-growing markets for ciclopirox and it is expected to grow at a CAGR of 5.8%, to reach a total valuation of US$ 3.6 Million by the end of 2033.
Due to the increasing population in China, the chances of suffering from fungal infections are very high. About 18% of the total population in China was found to be 60 years and older in 2020 and it is expected that this percentage will increase in the upcoming years. With the aging population the chances of suffering from fungal infection increases which drives the entire ciclopirox market.
The rise in the disposable income of the population and the entire development of the e-commerce space in China is also responsible for the growing ciclopirox market. The ease with which the ciclopirox medication can be bought in different online stores is also helping the overall market to grow, as people now prefer to buy products online more than traditional brick-and-mortar sales.
America has witnessed various incidences of burn damage in the last few years and there has been a high prevalence of skin diseases which is increasing at a very quicker rate in that entire region, which is responsible for causing various fungal infections.
Due to the increase in global warming, the overall temperature in the U.S. has significantly increased, and as people in that region are not used to such high temperatures, the prevalence of fungal infections is also increasing. With the increase in fungal infections, the demand for ciclopirox is growing in the entire U.S. region
The growing awareness of personal hygiene is also responsible for the ciclopirox market to grow substantially.
Creams are the most popular choice of product that is used for the treatment of fungal infections or any other kind of infection. There are several factors involved in the popularity of the cream-based product in comparison to any other product.
Not every Ciclopirox product is created with equal forms of purity. There are two different forms of purity, one is high (<98%), and the other is low (>98%). The different forms of purity have different applications of use.
The prominent players in the ciclopirox market are Kumar Organic Products Limited, Pharmaffiliates, Seqens Group, Fengchen Group Co., Ltd, MuseChem Chemicals, B JOSHI AGROCHEM PHARMA, Santa Cruz Biotechnology, Inc.
The majority of producers in the ciclopirox market, place a strong emphasis on innovation and ongoing product development while spending a lot of money on research and development to bring new products to market. The goal is to create new products that may be safer, more effective, or have fewer side effects.
Geographic expansion is another important business move that the leading players are considering. The business gains a lot from regional growth in terms of growing its market share, and it also benefits those who need the supply.
Fact.MR has provided detailed information about the price points of key manufacturers of ciclopirox positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.
What was the Global Ciclopirox Market Size Reported by Fact.MR for 2022?
The global ciclopirox market was valued at US$ 11.2 Million in 2022.
Who are the Major Players Operating in the Ciclopirox Market?
Prominent players in the ciclopirox market are Kumar Organic Products Limited, Pharmaffiliates, Seqens Group, Fengchen Group Co., Ltd, MuseChem Chemicals, B JOSHI AGROCHEM PHARMA, Santa Cruz Biotechnology, Inc.
What is the Estimated Valuation of the Ciclopirox Market in 2033?
The market is expected to reach a valuation of US$ 19.5 Million in 2033.
At What CAGR Did the Ciclopirox Market Exhibit Over the Last Five Years?
The historical growth rate of the ciclopirox market was 3.6% from 2018-2022.
What is the Estimated U.S. Market Size at the End of the Forecast Period (2023-33)?
The US market is expected to reach a valuation of US$ 6.0 Million in 2033.
What is the Estimated Chinese Market Size at the End of the Forecast Period (2023-33)?
The Chinese market is expected to reach a valuation of US$ 3.6 Million in 2033.
What is the Expected CAGR Percentage in the Cream-Based Product Formation of Ciclopirox at the End of the forecast period (2023-33)?
The CAGR in the cream-based product formation of the ciclopirox market is expected to grow by 5.3% during the assessment period 2023-33.
Ciclopirox Market